IBS/IBD – Society of Cannabis Clinicians https://www.cannabisclinicians.org Educating Healthcare Professionals about the Medical Use of Cannabis Sat, 29 Jul 2023 17:44:33 +0000 en-US hourly 1 https://wordpress.org/?v=6.2.3 https://www.cannabisclinicians.org/wp-content/uploads/2020/07/cropped-scc-flavicon-32x32.png IBS/IBD – Society of Cannabis Clinicians https://www.cannabisclinicians.org 32 32 Cannabidiol and Intestinal Motility: a Systematic Review https://www.cannabisclinicians.org/2023/07/29/cannabidiol-and-intestinal-motility-a-systematic-review/ Sat, 29 Jul 2023 17:44:33 +0000 https://www.cannabisclinicians.org/?p=28992 Cannabidiol (CBD) is a nonintoxicating cannabinoid extracted from the cannabis plant that is used for medicinal purposes. Ingestion of CBD is claimed to address several pathologies, including gastrointestinal disorders, although limited evidence has been generated thus far to substantiate many of its health claims. Nevertheless, CBD usage as an over-the-counter treatment for gastrointestinal disorders is likely to expand in response to increasing commercial availability, permissive legal status, and acceptance by consumers. This systematic review critically evaluates the knowledge boundaries of the published research on CBD, intestinal motility, and intestinal motility disorders. Research on CBD and intestinal motility is currently limited but does support the safety and efficacy of CBD for several therapeutic applications, including seizure disorders, inflammatory responses, and upper gastrointestinal dysfunction (ie, nausea and vomiting). CBD, therefore, may have therapeutic potential for addressing functional gastrointestinal disorders. The results of this review show promising in vitro and preclinical data supporting a role of CBD in intestinal motility. This includes improved gastrointestinal-related outcomes in murine models of colitis. These studies, however, vary by dose, delivery method, and CBD-extract composition. Clinical trials have yet to find a conclusive benefit of CBD on intestinal motility disorders, but these trials have been limited in scope. In addition, critical factors such as CBD dosing parameters have not yet been established. Further research will establish the efficacy of CBD in applications to address intestinal motility.

The post Cannabidiol and Intestinal Motility: a Systematic Review appeared first on Society of Cannabis Clinicians.

]]> A Survey of Cannabis Use among Patients with Inflammatory Bowel Disease (IBD) https://www.cannabisclinicians.org/2023/04/02/a-survey-of-cannabis-use-among-patients-with-inflammatory-bowel-disease-ibd-2/ Sun, 02 Apr 2023 13:16:41 +0000 https://www.cannabisclinicians.org/?p=28287 Inflammatory bowel diseases (IBDs) are chronic conditions of unknown cause or cure. Treatment seeks to reduce symptoms and induce and maintain remission. Many patients have turned to alternatives, such as cannabis, to alleviate living with IBD. This study reports the demographics, prevalence, and perception on cannabis use of patients attending an IBD clinic. Patients agreed to participate and completed an anonymous survey during their visit or online. Descriptive analysis, Fisher’s exact test, and Wilcoxon-Mann-Whitney rank-sum test were used. One hundred and sixty- two adults (85 males, 77 with CD) completed the survey. Sixty (37%) reported use of cannabis, of which 38 (63%) used it to relieve their IBD. A value of 77% reported low to moderate knowledge about cannabis, and 15% reported little to no knowledge. Among cannabis users, 48% had discussed use with their physician, but 88% said they would feel comfortable discussing medical cannabis for IBD. Most saw improvement of their symptoms (85.7%). A considerable number of patients with IBD use medical cannabis for their disease, unknown to their physician. The study reinforces the importance that physicians understand the role of cannabis in the treatment of IBD in order to appropriately counsel patients.

The post A Survey of Cannabis Use among Patients with Inflammatory Bowel Disease (IBD) appeared first on Society of Cannabis Clinicians.

]]> The Use of Cannabinoids in the Treatment of Inflammatory Bowel Disease (IBD): A Review of the Literature https://www.cannabisclinicians.org/2023/03/18/the-use-of-cannabinoids-in-the-treatment-of-inflammatory-bowel-disease-ibd-a-review-of-the-literature/ Sat, 18 Mar 2023 14:47:06 +0000 https://www.cannabisclinicians.org/?p=28094 Around the world, about 15 to 40% of individuals with inflammatory bowel disease (IBD) rely on cannabis and cannabinoids to reduce the need for other medications, as well as increase appetite and reduce pain. Whereas more and more patients continue to report benefits accruing from cannabis and cannabinoid usage in IBD, agreement relative to the use of cannabis and its derivatives in IBD remains unclear. This paper reviewed the interplay between cannabinoid use and IBD disease treatment, remission, or symptom relief. The study was conducted from a systematic review perspective. It involved consulting literature from published original research articles, noting outcomes, and performing a meta-analysis to identify trends and draw conclusions. The selected articles were those that had been published in a 10-year period ranging between 2012 and 2022. The motivation was to ensure recency and also relevance to contemporary scientific research and clinical environment practices.

The post The Use of Cannabinoids in the Treatment of Inflammatory Bowel Disease (IBD): A Review of the Literature appeared first on Society of Cannabis Clinicians.

]]> A Survey of Cannabis Use among Patients with Inflammatory Bowel Disease (IBD) https://www.cannabisclinicians.org/2023/03/17/a-survey-of-cannabis-use-among-patients-with-inflammatory-bowel-disease-ibd/ Sat, 18 Mar 2023 00:27:42 +0000 https://www.cannabisclinicians.org/?p=28084 Inflammatory bowel diseases (IBDs) are chronic conditions of unknown cause or cure. Treatment seeks to reduce symptoms and induce and maintain remission. Many patients have turned to alternatives, such as cannabis, to alleviate living with IBD. This study reports the demographics, prevalence, and perception on cannabis use of patients attending an IBD clinic. Patients agreed to participate and completed an anonymous survey during their visit or online. Descriptive analysis, Fisher’s exact test, and Wilcoxon-Mann-Whitney rank-sum test were used. One hundred and sixty- two adults (85 males, 77 with CD) completed the survey. Sixty (37%) reported use of cannabis, of which 38 (63%) used it to relieve their IBD. A value of 77% reported low to moderate knowledge about cannabis, and 15% reported little to no knowledge. Among cannabis users, 48% had discussed use with their physician, but 88% said they would feel comfortable discussing medical cannabis for IBD. Most saw improvement of their symptoms (85.7%). A considerable number of patients with IBD use medical cannabis for their disease, unknown to their physician. The study reinforces the importance that physicians understand the role of cannabis in the treatment of IBD in order to appropriately counsel patients.

The post A Survey of Cannabis Use among Patients with Inflammatory Bowel Disease (IBD) appeared first on Society of Cannabis Clinicians.

]]> The effect of medical cannabis in inflammatory bowel disease: analysis from the UK Medical Cannabis Registry https://www.cannabisclinicians.org/2023/01/06/the-effect-of-medical-cannabis-in-inflammatory-bowel-disease-analysis-from-the-uk-medical-cannabis-registry/ Fri, 06 Jan 2023 22:31:33 +0000 https://www.cannabisclinicians.org/?p=27426 annabis-based medicinal products (CBMPs) have shown promising preclinical activity in inflammatory bowel disease (IBD). However, clinical trials have not demonstrated effects on inflammation. This study aims to analyze changes in health-related quality of life (HRQoL) and adverse events in IBD patients prescribed CBMPs.

The post The effect of medical cannabis in inflammatory bowel disease: analysis from the UK Medical Cannabis Registry appeared first on Society of Cannabis Clinicians.

]]> The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients https://www.cannabisclinicians.org/2022/10/29/the-non-euphoric-phytocannabinoid-cannabidivarin-counteracts-intestinal-inflammation-in-mice-and-cytokine-expression-in-biopsies-from-uc-pediatric-patients-2/ Sat, 29 Oct 2022 20:58:18 +0000 https://www.cannabisclinicians.org/?p=27069 Patients with ulcerative colitis (UC) using marijuana have been reported to experience symptomatic benefit. Cannabidivarin (CBDV) is a safe non-psychoactive phytocannabinoid able to activate and desensitize TRPA1, a member of the TRP channels superfamily, which plays a pivotal role in intestinal inflammation. Here, we have investigated the potential intestinal anti-inflammatory effect of CBDV in mice and in biopsies from pediatric patients with active UC.

The post The non-euphoric phytocannabinoid cannabidivarin counteracts intestinal inflammation in mice and cytokine expression in biopsies from UC pediatric patients appeared first on Society of Cannabis Clinicians.

]]> Cannabinoid Therapeutic Effects in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials https://www.cannabisclinicians.org/2022/10/07/cannabinoid-therapeutic-effects-in-inflammatory-bowel-diseases-a-systematic-review-and-meta-analysis-of-randomized-controlled-trials/ Sat, 08 Oct 2022 01:05:05 +0000 https://www.cannabisclinicians.org/?p=26869 Inflammatory Bowel Disease (IBD) patients may benefit from cannabinoid administration supplementary therapy; currently no consensus on its effect has been reached. A systematic review of RCTs on cannabinoid supplementation therapy in IBD has been conducted; data sources were MEDLINE, Scopus, ClinicalTrials.

The post Cannabinoid Therapeutic Effects in Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials appeared first on Society of Cannabis Clinicians.

]]> Endocannabinoid Levels in Ulcerative Colitis Patients Correlate With Clinical Parameters and Are Affected by Cannabis Consumption https://www.cannabisclinicians.org/2021/09/22/endocannabinoid-levels-in-ulcerative-colitis-patients-correlate-with-clinical-parameters-and-are-affected-by-cannabis-consumption/ Wed, 22 Sep 2021 14:41:55 +0000 https://www.cannabisclinicians.org/?p=24449 Inflammatory bowel diseases (IBDs) are chronic, idiopathic, inflammatory, gastrointestinal disorders. The endocannabinoid system may have a role in the pathogenesis of IBD. We aimed to assess whether cannabis treatment influences endocannabinoids (eCBs) level and clinical symptoms of IBD patients.
Many cannabinoids display promising non-hallucinogenic bioactivities that are determined by the variable nature of the side chain and prenyl group defined by the enzymes involved in their synthesis.

The post Endocannabinoid Levels in Ulcerative Colitis Patients Correlate With Clinical Parameters and Are Affected by Cannabis Consumption appeared first on Society of Cannabis Clinicians.

]]> Cannabis and Cannabis Derivatives for Abdominal Pain Management in Inflammatory Bowel Disease https://www.cannabisclinicians.org/2021/07/05/cannabis-and-cannabis-derivatives-for-abdominal-pain-management-in-inflammatory-bowel-disease/ Mon, 05 Jul 2021 20:13:47 +0000 https://www.cannabisclinicians.org/?p=23604 For centuries, cannabis and its components have been used to manage a wide variety of symptoms associated with many illnesses. Gastrointestinal (GI) diseases are no exception in this regard. Individuals suffering from inflammatory bowel disease (IBD) are among those who have sought out the ameliorating properties of this plant. As legal limitations of its use have eased, interest has grown from both patients and their providers regarding the potential of cannabis to be used in the clinical setting.

The post Cannabis and Cannabis Derivatives for Abdominal Pain Management in Inflammatory Bowel Disease appeared first on Society of Cannabis Clinicians.

]]> Inflammatory Bowel Disease and Cannabis: A Practical Approach for Clinicians https://www.cannabisclinicians.org/2021/06/26/inflammatory-bowel-disease-and-cannabis-a-practical-approach-for-clinicians/ Sun, 27 Jun 2021 01:51:01 +0000 https://www.cannabisclinicians.org/?p=23484 This randomized, double-blind, placebo-controlled, cross-over study was conducted to evaluate the safety and efficacy of two-weeks of nightly sublingual cannabinoid extract (ZTL-101) in treating chronic insomnia (symptoms ≥three months).

The post Inflammatory Bowel Disease and Cannabis: A Practical Approach for Clinicians appeared first on Society of Cannabis Clinicians.

]]>